Author

D. Schramek

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:gene regulatory network inference· 5 Approach:genetic perturbation / CRISPR· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 4 Organism:mouse· 4 Research Focus:differential expression· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2

Frequent Co-Authors

R. Tsai· 5 shared A. Malik· 3 shared D. Dervovic· 2 shared E. Langille· 2 shared H. W. Jackson· 2 shared J. Reimand· 2 shared J. Wrana· 2 shared K. Al-Zahrani· 2 shared

Activity by Year

2019-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

R. Tsai

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Developmental priming of cancer susceptibility

I. Panzeri, L. Fagnocchi, S. Apostle, M. Tompkins, E. Wolfrum, Z. Madaj, G. Hostetter, Y. Liu, K. Schaefer, C.-H. Yang, A. Bergsma, A. Drougard, E. Dror, PERMUTE, D. Chandler, , J. A. Pospisilik

The paper shows that early life epigenetic variation can prime cancer-susceptibility states that persist into adulthood and correlate with poor prognosis in human cancers.

Nature Cancer · Jan 24, 2025Peer-reviewedCancer Biology

Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes

N. Adler, A. T. Bahcheli, K. Cheng, K. N. Al-Zahrani, M. Slobodyanyuk, D. Pellegrina, D. Schramek, J. Reimand

The paper analyzes the impact of mutational signatures from tobacco smoking and APOBEC activity on protein-truncating mutations in 12,341 cancer genomes across 18 types, showing their enrichment in key cancer pathways and tumor suppressors.

bioRxiv · Mar 19, 2023Cancer Biology

A two-step in vivo CRISPR screen unveils pervasive RNA binding protein dependencies for leukemic stem cells and identifies ELAVL1 as a therapeutic target

A. Vujovic, L. P. M. H. de Rooij, A. Keyvani Chahi, H. T. Chen, B. Yee, S. K. Loganathan, L. Liu, D. C. H. Chan, A. Tajik, E. Tsao, S. Moreira, P. Joshi, J. Xu, N. Wong, S. Zandi, , K. J. Hope

This study identifies RNA binding proteins essential for leukemic stem cell survival using an in vivo CRISPR screen and highlights ELAVL1 as a therapeutic target in AML.

bioRxiv · Jun 11, 2022 · PreprintCancer Biology

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

Y. Lu, T. Cho, S. Mukherjee, A. A. Malik, N. Gonzalez-Foutel, C. F. Suarez, D. Derovic, R. H. Oh, E. Langille, K. Al-Zahrani, Z. Lin, R. Tsai, V. Rotter, P. Ashton-Prolla, L. B. Chemes, , D. Schramek

This study uses CRISPR screens to identify factors regulating wild-type and mutant p53 stability, finding distinct regulators for different p53 mutants and their implications in cancer.

bioRxiv · Mar 13, 2022Cancer Biology

In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer

D. Dervovic, E. L. Y. Chen, A. Malik, S. Afiuni, J. Boucher, J. M. Berman, K. Teng, A. Ayyaz, Y. Lu, M. Narimatsu, G. Mbamalu, S. Loganathan, S. Martinez, R. Tsai, J.-B. Lee, , D. Schramek

The paper uses in vivo CRISPR screens to identify Serpinb9 and Adam2 as genes regulating immune therapy response in lung cancer, showing their roles in immune suppression and enhancement.

bioRxiv · Mar 13, 2022Cancer Biology

In vivo CRISPR screens reveal SCAF1 and USP15 as novel drivers of pancreatic cancer

S. Martinez, R. Weber, T. Woo, A. Malik, M. Geuenich, G. H. Jang, D. Dervovic, K. Al-Zahrani, R. Tsai, N. Fodil, P. Gros, S. S. Sidhu, S. Gallinger, G. Neely, K. Campbell, , D. Schramek

This study uses in vivo CRISPR screens to identify USP15 and SCAF1 as novel tumor suppressors in pancreatic cancer, with potential therapeutic implications.

bioRxiv · Mar 13, 2022Cancer Biology

Loss of epigenetic regulation disrupts lineage integrity, reactivatesmultipotency and promotes breast cancer

E. Langille, K. N. Al-Zahrani, Z. Ma, A. Malik, S. K. Loganathan, D. Trcka, J. Liu, K. Kozma, R. Tsai, K. Teng, R. Espin, S. Barutcu, T. Nguyen, R. Bremner, H. W. Jackson, , D. Schramek

This study identifies epigenetic regulators as tumor suppressors in breast cancer by showing their loss leads to lineage infidelity and reactivation of lactation programs.

bioRxiv · Oct 22, 2021 · PreprintCancer Biology

Comprehensive analysis of lncRNAs reveals candidate prognostic biomarkers in multiple cancer types

K. Isaev, L. Jiang, C. A. Lee, R. Tsai, F. Coutinho, P. B. Dirks, D. Schramek, J. Reimand

The paper identifies 179 prognostic lncRNAs across 29 cancer types using machine learning, showing their association with patient risk and tumor subtypes.

bioRxiv · Dec 2, 2019Cancer Biology